一线对比二线CDK4/6抑制剂治疗晚期乳腺癌的总生存期:随机临床试验
SONIA试验纳入1050例HR阳性、ERBB2阴性晚期乳腺癌患者,随机分配至一线或二线使用CDK4/6抑制剂联合内分泌治疗。绝经前亚组一线使用可能获益。
要点
- 一线使用CDK4/6抑制剂的3级以上不良事件更多(3400 vs 2242)。
- 绝经前患者一线使用可能改善OS(HR 0.53),但需进一步验证。
核心结论
- 一线使用CDK4/6抑制剂未改善OS,但增加治疗相关毒性。
研究设计与样本
- 3期随机对照试验,在荷兰多中心开展,纳入1050例HR阳性、ERBB2阴性晚期乳腺癌患者,1:1随机分配至一线或二线CDK4/6抑制剂联合内分泌治疗。
主要发现
- 中位随访58.5个月(95%CI 57.0-60.9),共606例死亡(57.7%)。
- 一线组3级以上不良事件更多(3400 vs 2242)。
临床怎么用
- 对于HR阳性、ERBB2阴性晚期乳腺癌,CDK4/6抑制剂可考虑二线使用以延迟暴露并减少毒性。
- 绝经前患者可能从一线使用CDK4/6抑制剂中获益,但需个体化评估。
局限性
- 绝经前亚组分析为事后分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are widely used in hormone receptor (HR)-positive, ERBB2-negative advanced breast cancer (ABC). The SONIA trial evaluates the optimal timing of CDK4/6i administration, either in first-line or second-line setting. OBJECTIVE: To determine whether first-line CDK4/6i use is superior to second-line use in terms of overall survival (OS) and to provide an updated analysis of the primary end point of progression-free survival (PFS) after 2 lines of therapy. DESIGN, SETTING, AND PARTICIPANTS: The phase 3 SONIA randomized clinical trial is a multicenter trial in the Netherlands. Patients with HR-positive, ERBB2-negative ABC who did not receive prior treatment for ABC were randomized 1:1 to receive CDK4/6i added to first-line or second-line endocrine therapy. Patients were enrolled between November 23, 2017, and September 1, 2021. Data cutoff for this prespecified updated analysis was September 1, 2024. Data were analyzed from February to May 2025. INTERVENTIONS: Aromatase inhibitor plus CDK4/6i as first-line treatment followed by fulvestrant as second-line treatment (CDK4/6i first-line group) vs aromatase inhibitor as first-line treatment followed by fulvestrant plus CDK4/6i as second-line treatment (CDK4/6i second-line group). MAIN OUTCOMES AND MEASURES: The primary end point was PFS after 2 lines of therapy. OS was a key secondary end point, with a prespecified analysis when all patients had 3 or more years of follow-up. RESULTS: Of 1050 enrolled patients, the median (IQR) age was 64 (16) years. A total of 524 were randomized to the CDK4/6i first-line group and 526 patients to the CDK4/6i second-line group. At a median follow-up of 58.5 months (95% CI, 57.0-60.9), 606 deaths (57.7%) had occurred. The median OS was 47.9 months (95% CI, 44.0-54.3) with first-line CDK4/6i and 48.1 months (95% CI, 44.7-52.0) with second-line CDK4/6i (hazard ratio [HR], 0.91; 95% CI, 0.77-1.07; P = .24). A post hoc subgroup analysis suggested an OS benefit with first-line use in premenopausal patients (HR, 0.53; 95% CI, 0.32-0.87) but not in postmenopausal patients (HR, 1.00; 95% CI, 0.84-1.19; P for interaction = .01). Among patients who discontinued second-line treatment, 257 of 303 in the first-line group (84.8%) and 303 of 360 in the second-line group (84.2%) received subsequent anticancer therapy, with similar treatment patterns. First-line CDK4/6i use was associated with more grade 3 or higher adverse events than second-line use (3400 vs 2242, respectively). CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, first-line CDK4/6i use did not improve OS compared with second-line use but did increase treatment-related toxic effects. Post hoc analysis suggests an OS benefit with first-line use in premenopausal patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03425838.
引用
- Wortelboer N, van Ommen-Nijhof A, Konings IR, et al. Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41712229. doi:10.1001/jamaoncol.2025.6585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。